Aquestive Therapeutics, Inc. (NASDAQ: AQST) Investor Alert: Deadline in Lawsuit on May 4, 2026

A deadline is coming up on May 4, 2026 in the lawsuit filed for certain investors of Aquestive Therapeutics, Inc. (NASDAQ: AQST) over alleged securities laws violations by Aquestive Therapeutics, Inc.

Investors who purchased shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) have certain options and there are strict and short deadlines running. Deadline: May 4, 2026. NASDAQ: AQST stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Warren, NJ based Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. Aquestive Therapeutics, Inc. (NASDAQ: AQST) reported that its annual Total Revenue declined from $57.56 million in 2024 to $44.54 million in 2025 and that its Net Loss increased from $44.13 million in 2024 to $83.78 million in 2025.

On January 9, 2026, Aquestive Therapeutics, Inc. disclosed that it was in receipt of an FDA letter that "identified deficiencies in the [Anaphylm] NDA that preclude discussion of labeling and post-marketing commitments at this time."

Shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) declined from $7.55 per share on October 20, 2025, to as low as $2.93 per share on January 30, 2026.

According to the complaint filed in the U.S. District Court for the District of New Jersey the plaintiff alleges on behalf of purchasers of Aquestive Therapeutics, Inc. (NASDAQ: AQST) common shares between June 16, 2025 and January 8, 2026, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between June 16, 2025 and January 8, 2026, the defendants made false and/or misleading statements and/or failed to disclose that Aquestive created the false impression that Aquestive was on track to receive approval for Aquestive's New Drug Application ("NDA") for Anaphylm by the January 31, 2026 Prescription Drug User Fee Act ("PDUFA") date, that the U.S. Food and Drug Administration ("FDA") identified deficiencies with Aquestive's NDA for Anaphylm precluding labeling discussions and post-marketing commitments, and that in order for the FDA to grant approval for any NDA, any deficiencies must be remedied, therefore the launch of Anaphylm was delayed, indicating that Aquestive failed to obtain approval for Anaphylm by the PDUFA date.

Those who purchased shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.